CN101094678A - 降低血中胆固醇用经口组合物 - Google Patents
降低血中胆固醇用经口组合物 Download PDFInfo
- Publication number
- CN101094678A CN101094678A CNA2005800458004A CN200580045800A CN101094678A CN 101094678 A CN101094678 A CN 101094678A CN A2005800458004 A CNA2005800458004 A CN A2005800458004A CN 200580045800 A CN200580045800 A CN 200580045800A CN 101094678 A CN101094678 A CN 101094678A
- Authority
- CN
- China
- Prior art keywords
- isoflavone
- dfa
- oral composition
- blood cholesterol
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明的目的是,提供使异黄酮的血中总胆固醇降低作用增强从而改善高胆固醇血症的组合物。本发明是含有双果糖酐和异黄酮及/或其衍生物作为有效成分的降低血中胆固醇用经口组合物。
Description
技术领域
本发明涉及使血中胆固醇降低的组合物。
背景技术
根据2002年日本国民营养调查,有11.5%的男性、18.2%的女性的血清总胆固醇值超过240mg/dL,因此推定存在相当数量的高胆固醇血症患者。已知血清总胆固醇上升的同时,冠状动脉疾病的相对危险也会连续升高(动脉硬化疾病诊疗指南2002年版,日本动脉硬化学会)(日语原名:「動脈硬化疾患診療ガイドライン2002年版、日本動脈硬化学会」)。对于这种状况,不仅是药物治疗,也正在尝试通过改善包括饮食在内的生活方式的治疗。
已知异黄酮类对高胆固醇血症有效(专利文献1:日本特开平9-255570号公报)。此外也报告了利用异黄酮类之一的大豆黄素使LDL-胆固醇减少,使HDL胆固醇提高,从而减少粥样硬变的危险性的方法(专利文献2:日本特开平11-139973号公报)。但是,在已大量食用富含异黄酮类的大豆的日本,高胆固醇血症仍在不断增加,从整个社会来看,异黄酮的效果并不充分。
作为寡糖的一种的双果糖酐(以下记为DFA),已知其具有双歧杆菌增殖作用(专利文献3:日本特公平3-5788号公报)、增加钙吸收量(专利文献4:日本专利第3514955号公报)、利尿作用(专利文献5:日本特开2003-321371号公报),但对于通过并用其和异黄酮降低胆固醇的效果仍不清楚。另一方面,在寡糖类中,已发明出组合有微细食物纤维和寡糖的高脂血症改善剂,特别是认为果糖寡糖有效(专利文献6:日本特开2000-154143号公报)。
专利文献1:日本特开平9-255570号公报
专利文献2:日本特开平11-139973号公报
专利文献3:日本特公平3-5788号公报
专利文献4:日本专利第3514955号公报
专利文献5:日本特开2003-321371号公报
专利文献6:日本特开2000-154143号公报
发明内容
本发明的目的是,提供使异黄酮的血中总胆固醇降低作用增强从而改善高胆固醇血症的组合物。
在精心研究可增强异黄酮的血中总胆固醇降低作用的手段的过程中发现:通过摄取DFA,可使异黄酮的血中总胆固醇降低作用增强。也就是说,本发明是合并使用DFA和异黄酮,发挥血中胆固醇降低作用的组合物。
本发明的主要构成是降低血中胆固醇用经口组合物,其特征在于,因为含有双果糖酐(difructose anhydride)和异黄酮及/或其衍生物作为有效成分,所以使异黄酮的胆固醇降低作用增强。
(1)降低血中胆固醇用经口组合物,其特征在于,含有双果糖酐(difructose anhydride)和异黄酮及/或其衍生物作为有效成分。
(2)降低血中胆固醇用经口组合物,其特征在于,含有双果糖酐(difructose anhydride)和大豆黄素及/或其衍生物作为有效成分。
(3)降低血中胆固醇用经口组合物,其特征在于,因为含有双果糖酐(difructose anhydride)和异黄酮及/或其衍生物作为有效成分,所以使异黄酮的胆固醇降低作用增强。
(4)降低血中胆固醇用经口组合物,其特征在于,因为含有双果糖酐(difructose anhydride)和大豆黄素及/或其衍生物作为有效成分,所以使大豆黄素的胆固醇降低作用增强。
(5)医药品或食品,其含有(1)~(4)中任一项所述的组合物。
(6)宠物动物用医药或宠物动物用饲料,其含有(1)~(4)中任一项所述的组合物。
本发明的含有DFA和异黄酮及/或其衍生物的组合物具有降低血中胆固醇的作用。
具体实施方式
本发明中所述的DFA是公知物质,是由2个果糖相互通过2点结合的脱水环状二糖。以往已知其存在于焦糖等内,工业上可通过下述方法制造,即、利用菊粉分解酶例如Arthrobacter sp.H65-7株产生的菊粉果糖转移酶(EC2.4.1.93)使菊粉发酵、利用Arthrobactemicotinovorans GS-9产生的左聚糖果糖转移酶(EC2.4.1.10)使左聚糖发酵来制造。根据两分子的果糖的结合方式不同,存在5种衍生物,分别称为DFAI、DFAII、DFAIII、DFAIV、DFAV。本发明中所述的DFA虽然指全部的DFA,但在本发明中,主要优选使用工业生产效率、精制后的稳定性等良好的DFAIII、DFAIV。
本发明涉及的经口组合物,因为含有DFA作为有效成分,所以可作为医药品类或饮食品类(包括宠物动物用饲饵料)的组合物利用。例如,可以为人或宠物动物用的医药品、饮食品、配方奶粉、经肠营养剂、健康饮食品、饲饵料添加物等,只要最终为可经口给与的形态,没有特别限定。本发明中最优选使用的是使DFA和异黄酮及/或其衍生物到达大肠之前不被吸收的形态,例如可以使其含在肠溶性胶囊内。此外,有效成分的含量无特别限定。
作为饮食品类组合物使用时,可直接使用DFA,或与其他食品或食品成分并用,根据适当的通常方法使用。此外,加工时,因为其热稳定性、酸稳定性都高,所以适合使用通常的食品加工方法,无任何问题。含有DFA的食品类经口组合物,可以为粉末、颗粒状、糊状、液状、悬浮状、片剂、胶囊剂等,没有特别限定。例如可使用甜味料、酸味料、维生素剂、其他制造健康饮料时常用的各种成分,制成健康饮料制剂。
作为医药品类组合物使用时,可将本有效成分以各种形态给药。其给药形态例如可以为片剂、胶囊剂、颗粒剂、散剂、糖浆剂等经口给药。所述各种制剂,可以根据常法,在主药中使用赋形剂、结合剂、崩解剂、润滑剂、矫味矫臭剂、助溶剂、悬浮剂、包衣剂等医药制剂技术领域中常用的已知辅助剂,制成制剂。
其使用量因症状、年龄、体重、剂型的不同而不同,通常情况下,成人经口给药时,每天每1kg体重为0.5~2000mg,优选在1~1000mg的范围给药。
本发明的异黄酮,是指通用名为染料木素、大豆黄素、黄豆黄素等具有异黄酮骨架的成分,其衍生物表示糖苷及/或其经乙酰化、丙二酰化等修饰的衍生物。在本发明中,优选使用在肠内细菌作用下变化为具有强活性的牛尿酚的大豆黄素及/或其衍生物。本发明中使用的异黄酮及/或其衍生物的来源,可任意为化学合成品、天然物的提取物及其加工品、植物本身。实施例
根据以下实施例更加详细地说明本发明,但这些仅仅是示例,本发明并不限于这些。
实施例1
对并用DFA和异黄酮时降低血浆总胆固醇作用的分析
用无异黄酮饲料预备饲养21只Wistar-ST系列雄性大鼠(6周龄)3天,然后根据体重分层法分为3组,每组n=7,如表1所示,给与含有0.25%的含异黄酮40%食品的基本饲料(Basal diet组)、用全体的1.5%的DFAIII取代基本饲料的纤维素后的饲料(DFAIII组)、用全体的1.5%的果糖寡糖取代基本饲料的纤维素后的饲料(FOS组),饲养19天。第20天从腹部大动脉采血,离心分离得到血浆,利用自动分析仪(DRI-CHEM 3500富士医疗公司制(FUJI FILM Medical)),测定血浆总胆固醇。
其结果如表2所示。表中a、b表示具有不同符号的数值之间有显著差异。根据Sheffe法的Basal diet组和DFAIII组的显著差异p=0.051,认为有增强趋势。HDL胆固醇在DFAIII组略低,但各组没有大的差异。
该结果显示,与仅摄取异黄酮的组相比,通过摄取DFA,血清总胆固醇呈降低趋势。该效果在公知的具有高脂血症改善效果的寡糖的果糖寡糖中未发现。
表1
Basal diet | DFAIIIdiet | FOS diet | |
酪蛋白糊精玉米油混合矿物质混合维生素Choline BitartateL-胱氨酸抗氧化剂纤维素异黄酮(40%品)DFAIIIFOS蔗糖 | 2004537035102.530.014802.500143.986 | 2004537035102.530.014652.5150143.986 | 2004537035102.530.014652.5015143.986 |
Total(g) | (g) 1000 | 1000 | 1000 |
表2
Basal Diet | DFAIII 1.5% | FOS 1.5% | |
Total cholesterol(mg/L)HDL-cholesterol(mg/L) | 7.6±0.5ab4.2±0.3 | 6.1±0.3a3.7±0.4 | 7.7±0.4b4.1±0.3 |
Claims (4)
1.降低血中胆固醇用经口组合物,其特征在于,含有双果糖酐和异黄酮及/或其衍生物作为有效成分。
2.降低血中胆固醇用经口组合物,其特征在于,含有双果糖酐和大豆黄素及/或其衍生物作为有效成分。
3.医药品或食品,其含有权利要求1或2所述的组合物。
4.宠物动物用医药或宠物动物用饲料,其含有权利要求1或2所述的组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005005738A JP2006193459A (ja) | 2005-01-12 | 2005-01-12 | 血中コレステロール低下用経口組成物 |
JP005738/2005 | 2005-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101094678A true CN101094678A (zh) | 2007-12-26 |
Family
ID=36677551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800458004A Pending CN101094678A (zh) | 2005-01-12 | 2005-12-27 | 降低血中胆固醇用经口组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080132466A1 (zh) |
EP (1) | EP1839663A4 (zh) |
JP (1) | JP2006193459A (zh) |
CN (1) | CN101094678A (zh) |
WO (1) | WO2006075523A1 (zh) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63269962A (ja) * | 1987-04-28 | 1988-11-08 | Natl Food Res Inst | 食品素材 |
JPH05168419A (ja) * | 1991-06-05 | 1993-07-02 | Mitsubishi Kasei Corp | 動物の脂肪低減剤及びこれを用いる動物の飼育方法 |
NZ252051A (en) * | 1992-05-19 | 1996-10-28 | Graham Edmund Kelly | Health supplement comprising a phyto-oestrogen selected from genistein, daidzein, biochanin and/or formononetin |
JPH09255570A (ja) * | 1996-03-21 | 1997-09-30 | Fujitsuko Kk | 血中脂質濃度を低減させる薬剤及び可食性組成物 |
US5855892A (en) * | 1997-09-19 | 1999-01-05 | Potter; Susan M. | Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease |
US7285297B1 (en) * | 1999-04-23 | 2007-10-23 | Archer-Daniels-Midland Company | Method of reducing low density liproprotein cholesterol concentration |
JP2004161619A (ja) * | 2002-11-11 | 2004-06-10 | Fancl Corp | 骨形成促進組成物 |
KR100993978B1 (ko) * | 2002-04-26 | 2010-11-11 | 니혼 텐사이 세이토 가부시키가이샤 | 변통개선제 |
JP4613017B2 (ja) * | 2004-02-16 | 2011-01-12 | 株式会社ファンケル | ダイフラクトースアンハイドライド含有経口組成物 |
JP4871497B2 (ja) * | 2004-07-06 | 2012-02-08 | 株式会社ファンケル | Dfa含有難吸収水溶性生理活性物質吸収促進剤。 |
JP4723849B2 (ja) * | 2004-11-17 | 2011-07-13 | 株式会社ファンケル | ダイフラクトースアンハイドライド含有経口組成物 |
-
2005
- 2005-01-12 JP JP2005005738A patent/JP2006193459A/ja active Pending
- 2005-12-27 CN CNA2005800458004A patent/CN101094678A/zh active Pending
- 2005-12-27 EP EP05822703A patent/EP1839663A4/en not_active Withdrawn
- 2005-12-27 US US11/813,731 patent/US20080132466A1/en not_active Abandoned
- 2005-12-27 WO PCT/JP2005/023880 patent/WO2006075523A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2006075523A1 (ja) | 2006-07-20 |
EP1839663A4 (en) | 2008-03-05 |
US20080132466A1 (en) | 2008-06-05 |
JP2006193459A (ja) | 2006-07-27 |
EP1839663A1 (en) | 2007-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0265046B1 (en) | Balanced fiber composition | |
US6869621B2 (en) | Diet composition comprising raw foods and dietary fibers | |
JP3966689B2 (ja) | リパーゼ阻害剤 | |
EP2226071A1 (en) | Composition for oral administration | |
US20090258111A1 (en) | Highly bioavailable oral administration composition of cryptoxanthin | |
JP2007223914A (ja) | 経口投与組成物 | |
CN101056644B (zh) | 含有双果糖酐的经口组合物 | |
JP2002255846A (ja) | 経口組成物 | |
EP1656943A1 (en) | Extract from plant of japanese parsley family and process for producing the same | |
JP2001269135A (ja) | 体タンパク質蓄積効率を亢進する栄養組成物 | |
US20100197611A1 (en) | Alternative agent with vitamin d-like activity and an improving agent for intestinal function | |
CN101094678A (zh) | 降低血中胆固醇用经口组合物 | |
Jaddu et al. | Hub of health: Nutraceuticals and functional foods | |
JPH06256180A (ja) | 腸内環境改善組成物 | |
JPH0995448A (ja) | 血中ビオチン濃度の増加方法およびビオチン含有飲食品 | |
KR100466580B1 (ko) | 복분자 추출물을 유효성분으로 포함하는 비만 방지 또는 치료용 조성물 | |
JP2006348054A (ja) | リパーゼ阻害剤 | |
TWI714413B (zh) | 以含有硫酸軟骨素的豬軟骨萃取物作為有效成分的血壓上升抑制劑及含有其的食品組成物 | |
CN1947722B (zh) | 一种餐时血糖调节剂及其制备工艺 | |
JP2005126429A (ja) | 免疫賦活剤、食品及び液状食品組成物 | |
JP2005295840A (ja) | 健康こんにゃく | |
KR101800999B1 (ko) | 친환경적으로 재배된 당유자 통밀감분말을 유효성분으로 함유하는 비만억제용 조성물 | |
AU2003254818A1 (en) | Remedy | |
Singh et al. | Development and evaluation of food multi-mix (FMM) | |
TW202426025A (zh) | 睡眠改善劑 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1110021 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1110021 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20071226 |